Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA

Stock Information for Codexis Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Codexis Inc.

Codexis Enters into $60 Million Term Loan Facility with Trinity Capital
Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities
Codexis to Report Third Quarter 2026 Financial Results on November 12
Codexis to Participate in Cantor Global Healthcare Conference 2026
Codexis Reports Second Quarter 2026 Financial Results
Codexis Appoints David Butler, PhD, to Strategic Advisory Board
Codexis to Report Second Quarter 2026 Financial Results on August 11
Codexis Announces Proposed Public Offering of Common Stock

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.